BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

11.11B

Market cap11.11B

Price-Earnings ratio

157.75

Price-Earnings ratio157.75

Dividend yield

—

Dividend yield—

Average volume

2.48M

Average volume2.48M

High today

$59.50

High today$59.50

Low today

$57.17

Low today$57.17

Open price

$58.66

Open price$58.66

Volume

1.86M

Volume1.86M

52 Week high

$70.98

52 Week high$70.98

52 Week low

$49.26

52 Week low$49.26

Stock Snapshot

The current BioMarin(BMRN) stock price is $57.39, with a market capitalization of 11.11B. The stock trades at a price-to-earnings (P/E) ratio of 157.75.

As of 2026-11-02, BioMarin(BMRN) stock has fluctuated between $57.17 and $59.50. The current price stands at $57.39, placing the stock +0.4% above today's low and -3.5% off the high.

The BioMarin(BMRN)'s current trading volume is 1.86M, compared to an average daily volume of 2.48M.

During the past year, BioMarin(BMRN) stock moved between $49.26 at its lowest and $70.98 at its peak.

BMRN News

Investing.com 4h

Biomarin earnings on deck: Amicus integration in focus - Investing.com

...

Simply Wall St 3d

How Investors Are Reacting To BioMarin Pharmaceutical Fabry Disease Licensing Deal

On 29 October 2026, GC Biopharma and Hanmi Pharm announced an exclusive worldwide license agreement granting BioMarin Pharmaceutical rights outside Korea to HM1...

Simply Wall St 6d

BioMarin Pharmaceutical Could Be 24% Undervalued Ahead Of Its November 2 Results Call

Advertisement Event overview and why it matters for BioMarin Pharmaceutical investors BioMarin Pharmaceutical (BMRN) has scheduled a conference call and webca...

Analyst ratings

77%

of 31 ratings

Buy

77.4%

Hold

22.6%

Sell

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Boston Scientific

Alnylam Pharmaceuticals

KKR & Co

NRG Energy

Mastec

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.